Structure-activity relationship of cyanine tau aggregation inhibitors.
about
Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's diseaseTau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseStructural determinants of Tau aggregation inhibitor potencyDiscovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.Structure and mechanism of action of tau aggregation inhibitors.Advances in tau-based drug discovery.Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.Tau as a therapeutic target in neurodegenerative disease.Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitroCornel Iridoid Glycoside Attenuates Tau Hyperphosphorylation by Inhibition of PP2A DemethylationModulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Potential synergy between tau aggregation inhibitors and tau chaperone modulators.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.Structure-activity relationship of cyclic thiacarbocyanine tau aggregation inhibitors.Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.Aggregation behavior of novel heptamethine cyanine dyes upon their binding to native and fibrillar lysozyme.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?Detection and Quantification Methods for Fibrillar Products of In Vitro Tau Aggregation Assays.Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms
P2860
Q24627125-F4AE1D6D-09E5-4605-AB93-2ED8BE19C936Q26739412-532CEBE5-B984-404E-A691-2C446E57B8F9Q30353954-7E06491D-EB82-403A-A09A-56218D51626BQ33861802-AE6902AA-56D3-4B2C-9341-07AF05C16029Q34902096-50AAFE60-7596-4185-A122-74EDC1D39914Q35321539-51694749-B0D9-4008-A717-1F8F51108AD2Q36779614-9CEEDC22-9CF6-47A3-9785-97CD850E94C0Q36970350-359536AD-48DB-46C5-BDB5-4BFA153BBE63Q37419558-5F384AC2-28BC-4ED4-A8D2-1B8466BF3D30Q37433111-366E9ED7-619D-41CD-AFB6-1C6B974F09F9Q37841631-B7CC4128-E35D-4F5A-AC72-94A63AA02E7EQ38138165-AC738A1A-5076-476E-95AD-8A70F6C7FF9AQ38715233-54633379-F259-463A-860B-3604607003C4Q39035486-A8F412FD-6B8C-450A-864A-A9DF9A54268DQ42060140-A76F733E-2945-421D-8FC8-EC97AAD4F1AFQ46128904-3BDD5146-0CFD-4719-9DA2-48BDA283BDD0Q46389762-55EF5140-EC1A-45E3-A623-F617467EC384Q48239696-C9730FE4-25DB-46CC-90EB-93D71DC694C4Q51263482-5C273ECF-6FF1-45EE-8116-F1F3E6DD2F3DQ57159243-6B7EE3FB-44CE-4410-854F-43B62D2864A8
P2860
Structure-activity relationship of cyanine tau aggregation inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Structure-activity relationship of cyanine tau aggregation inhibitors.
@en
Structure-activity relationship of cyanine tau aggregation inhibitors.
@nl
type
label
Structure-activity relationship of cyanine tau aggregation inhibitors.
@en
Structure-activity relationship of cyanine tau aggregation inhibitors.
@nl
prefLabel
Structure-activity relationship of cyanine tau aggregation inhibitors.
@en
Structure-activity relationship of cyanine tau aggregation inhibitors.
@nl
P2093
P2860
P356
P1476
Structure-activity relationship of cyanine tau aggregation inhibitors
@en
P2093
Edward Chang
Jeff Kuret
Karen E Duff
Nicolette S Honson
P2860
P304
P356
10.1021/JM900116D
P407
P577
2009-06-01T00:00:00Z